Korean J Gastroenterol.  2015 Oct;66(4):183-185. 10.4166/kjg.2015.66.4.183.

Hyperuricemia as a Novel Risk Factor for Colorectal Adenomatous Polyp

• Lee JW
• Im JP

• KMID: 2373338
• DOI: http://doi.org/10.4166/kjg.2015.66.4.183

Abstract

No abstract available.

MeSH Terms

Adenoma/*diagnosis
Colorectal Neoplasms/*diagnosis
Female
Humans
Male
Metabolic Syndrome X/*diagnosis
Uric Acid/*blood
Uric Acid

Reference

References

1. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47:127–141.

2. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64:1637–1649.

3. Schoen RE, Razzak A, Yu KJ, et al. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology. 2015. DOI: doi:10.1053/j.gastro.2015.07.055. [Epub ahead of print].

4. Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2009; 7:1272–1278.

5. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982; 23:835–842.

6. Pendergrass CJ, Edelstein DL, Hylind LM, et al. Occurrence of colorectal adenomas in younger adults: an epidemiologic necropsy study. Clin Gastroenterol Hepatol. 2008; 6:1011–1015.

7. Ben Q, An W, Jiang Y, et al. Body mass index increases risk for colorectal adenomas based on metaanalysis. Gastroenterology. 2012; 142:762–772.

8. Nam SY, Kim BC, Han KS, et al. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol. 2010; 8:443–450. e1-e2.

9. Jorgensen B, Knudtson J. Stop cancer colon. Colorectal cancer screening–updated guidelines. S D Med. 2015. Spec No:82–87.

10. Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a metaanalysis. Br J Cancer. 2011; 104:882–885.

11. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010; 10:51.

12. Stocks T, Lukanova A, Bjørge T, et al. Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer. 2011; 117:2398–2407.

13. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6:30–38.

14. Neogi T. Clinical practice. Gout. N Engl J Med. 2011; 364:443–452.

15. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005; 45:18–20.

16. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359:1811–1821.

17. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol. 2005; 20:1410–1415.

18. Kim HJ, Kim JE, Jung JH, et al. Uric acid is a risk indicator for metabolic syndrome-related colorectal adenoma: results in a Korean population receiving screening colonoscopy. Korean J Gastroenterol. 2015; 66:202–208.

19. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a metaanalysis. JAMA. 2006; 295:74–80.

20. Cai H, Zhang G, Wang Z, Luo Z, Zhou X. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and metaanalysis. PLoS One. 2015; 10:e0126944.

21. Makar GA, Holmes JH, Yang YX. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014; 106:djt374.